The possibility to inhibit tumor growth by interfering with the formation of new vessels, which most neoplasias depend on, has recently raised considerable interest. An angiogenic switch, in which proliferating cells acquire the ability to direct new vessel formation, is thought to be an early step in the natural history of solid tumors. Using a transgenic model of breast cancer, which shows many similarities to its human counterpart, including ability to metastasize, we targeted angiostatin production to an early stage of tumor formation. Liposome-delivered angiostatin considerably delayed primary tumor growth and, more importantly, inhibited the appearance of lung metastases. These findings can be relevant to the design of therapeutic intervention in humans.
Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer / M.G. Sacco, M. Caniatti, E.M. Catò, A. Frattini, G. Chiesa, R. Ceruti, F. Adorni, L. Zecca, E. Scanziani, P. Vezzoni. - In: CANCER RESEARCH. - ISSN 0008-5472. - 60:10(2000 May 15), pp. 2660-2665.
|Titolo:||Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer|
CANIATTI, MARIO (Secondo)
SCANZIANI, EUGENIO (Penultimo)
|Parole Chiave:||Animals ; Receptor, erbB-2 ; Antineoplastic Agents ; Humans ; Mice ; Gene Therapy ; Mice, Transgenic ; Liposomes ; Membrane Proteins ; Peptide Fragments ; Receptors, Virus ; Neoplasm Metastasis ; Mammary Neoplasms, Experimental ; Angiostatins ; Plasminogen ; Female|
|Settore Scientifico Disciplinare:||Settore VET/03 - Patologia Generale e Anatomia Patologica Veterinaria|
Settore BIO/14 - Farmacologia
|Data di pubblicazione:||15-mag-2000|
|Appare nelle tipologie:||01 - Articolo su periodico|